on B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Announces Half-Year Financial Results
BRAIN Biotech AG has released its financial figures for the first half of the 2024/25 fiscal year, reporting €25.2 million in revenue, a decrease of 7.2% from the previous year. The decline is attributed to economic challenges and delays in contract finalizations. The key BRAINBiocatalysts segment saw slight growth at €22.7 million, while BRAINBioIncubator's revenue dropped to €2.5 million. Adjusted EBITDA for both segments faced declines, influencing the overall financial standing.
CEO Adriaan Moelker highlighted the impacts of the tough economic environment on research services. Despite a high liquidity of €14.9 million, BRAIN Biotech AG adjusted its fiscal forecast, anticipating stagnant sales for the full fiscal year.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news